Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomix Appoints Prospect Genomics Founder, Exelixis Founder to Board

NEW YORK, July 19 - Structural Genomix has appointed Bill Rutter and Stelios Papadopoulos to the company's board of directors, the company said Thursday.

Rutter is a co-founder of Prospect Genomics, a San Francisco-based developer of protein structure prediction software  that was acquired in April by Structural Genomix. In addition, Rutter is a founder and chairman emeritus of Chiron, and has served as chairman of the biochemistry and biophysics department at the University of California, San Francisco.

Papadopoulos currently serves as a managing director in investment banking at SG Cowen, specializing in the biotechnology and pharmaceutical sectors. He is a founder and chairman of the board of Exelixis, and a founder and director of Anadys Pharmaceuticals, CellZome, and CellFate.

The addition of Papadopoulos and Rutter brings the number of company directors to eight.

"With their collective knowledge and experience in drug discovery, investment banking, and management, Stelios and Bill bring tremendous value to our board," George Poste, chairman of Structural Genomix, said in a statement. "Stelios' commitment to strategic business development will facilitate SGX's success, while Bill's background in both academia and commercial life sciences will ensure SGX's dedication to both innovation and sound operations."  
The Scan

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.